Scribe Therapeutics
Wardah Masud has five years of work experience. Wardah began their career in 2018 as an Undergraduate Research Assistant at the University of Toronto. In 2019, they completed two Undergraduate Degree Research Projects, one at the University of Toronto and one at Københavns Universitet - University of Copenhagen. In 2021, they joined Zymergen as a Research Associate, and in 2022 they began working at Scribe Therapeutics as a Research Specialist, Therapeutic Discovery.
Wardah Masud completed their Honours Bachelor's of Science from the University of Toronto in 2020, with a major in Genetics and Biology, and achieved Distinction.
Scribe Therapeutics
1 followers
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.